Arterial Stiffness Clinical Trial
Official title:
LOVE-COARCT Study: Long-term Outcomes and Vascular Evaluation After Coarctation of the Aorta Treatment
Background: Coarctation of the aorta (CoA) can be treated using surgery, balloon angioplasty or stent implantation. Although short-term results are excellent with all three treatment modalities, long term cardiovascular (CV) morbidity and mortality remain high, likely due to persistently abnormal vascular function. The effects of treatment modality on long term vascular function remain uncharacterized. The goal of this study is to assess vascular function in this patient population for comparison among the treatment modalities. Methods: Vascular function in large and small arteries will be prospectively assessed fusing multiple non-invasive modalities, and the results will be compared among the three groups of CoA patients previously treated using surgery, balloon angioplasty or stent implantation after frequency matching for confounding variables. A comprehensive vascular function assessment protocol was created to be used in 7 centers. The primary outcome is arterial stiffness measured by arterial tonometry. Inclusion and exclusion criteria were carefully established after consideration of several potential confounders. Sample size was calculated for the primary outcome variable. Conclusions: Treatment modalities for CoA may have distinct impact on large and small arterial vascular function. The results of this study will help identify the treatment modality that is associated with the most optimal level of vascular function, which, in the long term may reduce CV risk.
Study overview. This cross-sectional prospective observational study of patients with CoA
previously treated using one of three treatment modalities assesses if treatment type is
associated with differences in vascular function. The three treatment groups will be
frequency-matched for key confounding variables.
Study feasibility. The investigators assembled a multi-disciplinary team with proven
expertise in epidemiology, clinical trial design, congenital heart disease, non-invasive
imaging, interventional cardiology, vascular function assessment, preventive cardiology and
statistical analysis. A multicenter design is used to ensure sufficient statistical power in
evaluating the hypothesis.
Participating centers and study core laboratories. Patients are recruited at six large
pediatric cardiac centers from Portugal and USA.
Screening procedures. The medical records of potentially eligible patients are screened by a
local study investigator using a pre-specified screening form to ensure that they satisfy our
selection criteria.
Overview of the study workflow. Study procedures will occur in a one- or two-day visit. Upon
arrival for testing, formal consent for participation will be obtained. Assessment of
arterial stiffness, endothelial function, and blood sampling for biomarkers will be done
while fasting. Cardiopulmonary stress test will be performed on the same day. CMR and
ambulatory blood pressure monitoring (ABMP) will be arranged for the same or for the
following day. When the study tests cannot be completed at the first visit, they will be
completed within 3 months of the first visit. The study protocol was approved by the
Institutional Review Board or Institutional Ethics Committee at each participating center,
and informed consent and assent will be obtained, depending on age, from patients and their
parents/legal guardians before trial enrollment.
Recruitment. A review of the patient database at each participating institution will be
performed to assemble a cohort of patients with CoA who have previously undergone treatment
with balloon dilation, surgery or stenting. Study data will be collected and managed using
REDCap electronic data capture tools hosted at Boston Children's Hospital.
Data collection. A retrospective chart review will be performed to collect demographic and
clinical data including severity of coarctation, type and details of CoA treatment and
presence of associated conditions.
Diagnostic procedures.
Arterial Stiffness Plan & Rationale:
Measurements: Carotid-femoral PWV (cfPWV) will be measured using applanation tonometry.
Segmental PWV is measured using CMR. Segmental measures of arterial distensibility will be
measured using CMR. Other parameters that describe arterial stiffness reflect the
relationship of arterial change in diameter to change in pressure and include aortic strain
(relative change in diameter), compliance (absolute change in diameter in response to a
change in pressure), distensibility (relative change in diameter in response to a change in
pressure), and the aortic stiffness β index (distensibility using the logarithmic conversion
of the relative pressure). Applanation tonometry, which uses a probe or tonometer to record
the pulse wave with a transducer, is the most widely accepted method for estimating PWV and
both the NIHem (Cardiovascular Engineering, Inc., Norwood, MA USA) and the SphygmoCor (AtCor
Medical, West Ryde, NSW, Australia) devices have been validated in large cohort trials. Both
devices will be used, based on local availability.
Endothelial Function Measurements: Endothelium-dependent reactive hyperaemia index and
augmentation index will be measured using the EndoPAT 2000 system (Itamar Medical, Caesarea,
Israel). The protocol includes measures to minimize the influence of the autonomic nervous
system.
Pulse Waveform Analysis: Central aortic pressure and pulse pressure will be measured using
applanation tonometry). Augmentation index will be measured using applanation tonometry and
Endo-PAT. CAP, PP and AIx can be measured non-invasively using radial or carotid applanation
tonometry (and Endo-PAT for AIx), calibrated by the peripheral diastolic and mean arterial
pressure. Both the NIHem system and the SphygmoCor device were used.
Blood Pressure Phenotype will be measured using conventional standard techniques including
auscultatory right arm BP measurement, measurement of BP gradient between arm and leg, BP
response during treadmill exercise stress testing (ET) and ABPM. Based on the auscultatory BP
and ABPM results, the appropriate children and adult guidelines will be used to classify
patients. Patients currently on antihypertensive medication will be classified as
hypertensive.
Biomarkers: The researchers will measure biomarkers of endothelial function (total oxides of
nitrogen- NOx and ADMA), inflammation (hs-CRP), vascular wall function (VCAM-1 and IL-1β) and
vascular remodeling (MMP-2; MMP-9 and TGF-beta1). NOx will be determined by chemiluminescence
(Sievers NOAnalyzer 280i) and all remaining measurements will be performed with appropriate
enzyme-linked immunosorbent assay (ELISA) kits: ADMA (Sunred Biological Technology, Shanghai,
China); hs-CRP (BoosterBio, Pleasanton, USA); VCAM-1; IL-1β; MMP-9; MMP-2 and TGFβ-1
(RayBiotech, Inc. Norcross, USA).
Left Ventricular Mass Assessment by CMR. The altered blood pressure phenotype that persists
after CoA treatment represents an increase in afterload that leads to LV hypertrophy. Our CMR
protocol will include sequences that allow this quantification.
Cardiovascular Health Assessment: The researchers will assess health factors (blood pressure,
total cholesterol, plasma glucose), behaviors (smoking, body mass index BMI, physical
activity and diet) and family history of cardiovascular disease and risk factors. A
questionnaire was implemented to assess family history of CV disease and ICVH according to
the procedures and recommendations of the American Heart Association.
Statistical Considerations. The treatment groups will be frequency-matched for documented
confounders. The confounding variables will include: (a) Age at treatment; (b) Current age;
(c) Bicuspid aortic valve as it is associated with impaired aortic elasticity. Because of the
relatively large number of matching variables and three treatment groups, matching individual
subjects was not feasible. During analysis, the treatment groups will be compared for each of
these confounding variables and appropriate adjustments made, if needed. Differences in the
confounding variables across the three treatment groups will be evaluated using Fisher's
exact test for severity of coarctation and the Kruskal-Wallis test for age at treatment,
current age and bicuspid aortic valve. The primary outcome variable will be carotid-femoral
PWV assessed by tonometry. Differences in cfPVW across groups will be explored using one-way
analysis of variance. If differences in matching variables are detected among the groups,
adjustment will be made using analysis of covariance. Post-hoc analyses will be performed as
necessary.
Sample size estimates were obtained based on prior data that show that ascending- descending
PWV measured by CMR is 3.3±0.6 m/s in normal subjects and 4.7±1.1 m/sec after CoA surgery.22,
70 Sample size estimates for comparison of PVW between three equal sized treatment groups
(assuming overall significance level=0.05 and power=0.8) are shown in table 2. The
investigators plan on recruiting 24 to 30 patients in each group for a total sample size of
72 to 90.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06133634 -
Fisetin to Improve Vascular Function in Older Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05872139 -
Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging
|
N/A | |
Recruiting |
NCT04558450 -
Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Completed |
NCT02226055 -
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
|
N/A | |
Completed |
NCT01559896 -
Egg Protein Hydrolysate and Vascular Function
|
N/A | |
Completed |
NCT04049162 -
Blueberry Enhances Activity and Cognition Through Increased Vascular Efficiency
|
N/A | |
Not yet recruiting |
NCT06440369 -
Physical Activity and Cardiovascular Risk
|
N/A | |
Completed |
NCT05537246 -
The Relationship Between Arterial Stiffness and Hemodynamic Responses in Patients With Spinal Anesthesia
|
||
Completed |
NCT06151054 -
Relationship Between Aortic Parietal Inflammation on 18F-FDG PET Scan and Arterial Stiffness as a Function of Age
|
||
Completed |
NCT02218268 -
Arterial Stiffness in Type I Diabetes Mellitus
|
N/A | |
Completed |
NCT00547040 -
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
|
||
Completed |
NCT02821780 -
CADASIL Disease Discovery
|
||
Completed |
NCT05719090 -
Acute Effects of Autoregulated and Non-autoregulated Blood Flow Restrictive Exercise on Indices of Arterial Stiffness
|
N/A | |
Completed |
NCT04549324 -
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
|
||
Completed |
NCT05022498 -
Individual Variability of Coronary Heart Disease Risk Markers and Sleep Responses to Exercise
|
N/A | |
Completed |
NCT03415880 -
Light Intensity Physical Activity Trial
|
N/A | |
Completed |
NCT03560804 -
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
|
N/A |